TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance

We recently published 10 Stocks Bleeding Early. TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the companies that stood stronger last week.

TG Therapeutics fell for a third day on Monday, shedding 18 percent to close at $28.72 apiece as investors soured on a lower-than-expected full-year sales guidance.

In a statement, TG Therapeutics, Inc. (NASDAQ:TGTX) raised its revenue outlook for Briumvi to a range of $570 million to $575 million from the $560 million previously, but was still lower than the $596 million as expected by analysts.

The company also upped its total global revenue target to $585 million for the full year 2025 from its previous outlook of $575 million year-on-year.

In the second quarter of the year, TG Therapeutics, Inc. (NASDAQ:TGTX) posted a net income 310-percent expansion in net income to $28.19 million from $6.88 million in the same period last year.

Total revenues were also higher by 93 percent to $141 million from $73 million in the same comparable period.

The company also swung to a net profit of $33 million from a $3.8-million net loss in the same period last year.

While we acknowledge the potential of TGTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.